Core Insights - Sinovac's inactivated hepatitis A vaccine, Hai'erlaifu®, has won the exclusive bid for the public market project in Oman for the 2026-2027 fiscal year, marking a significant achievement for the company in the Middle East and North Africa region [1] - Since entering the Omani market in 2022, Sinovac has established a reliable reputation based on consistent product quality, timely supply, and logistics support, which contributed to winning this exclusive supply qualification [1] - The Gulf Cooperation Council (GCC), a major political and economic organization in the Gulf region, has historically relied on multinational pharmaceutical companies for vaccine supplies, making Sinovac's success a notable breakthrough in gaining trust from GCC countries [1] Company Performance - Sinovac's Hai'erlaifu® vaccine has supplied over 130 million doses to nearly 50 countries and regions globally, making it one of the most widely used inactivated hepatitis A vaccines [1]
国产甲肝疫苗独家中标阿曼两年订单